Intorio, Corp. announced that effective May 16, 2024, Gagi Gogolashvili, the previous sole officer and director and majority shareholder of the company entered into a stock purchase agreements for the sale of 2,000,000 shares of Common Stock of the Company, representing approximately 89% of the issued and outstanding shares of Common Stock of the Company as of such date, to six (6) accredited investors, and as such they are able to unilaterally control the election of its board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of its Company. Upon the resignation of Mr. Gogolashvili from all executive officer positions with the Company, including Chief Executive Officer, effective May 16, 2024, Dr. Han-Wen Ou was appointed as Chief Executive Officer.

Dr. Ou has received the following degrees: a Bachelor of Science (BSc) from Taipei Medical University, a Master of Functional Medicine (MSc) from University of Western State (UWS), and a Doctor of Clinical Nutrition (PhD, DCN) from Maryland University of Integrative Health (MUIH). Dr. Ou was formerly a Resident at Taipei Veterans General Hospital (TVGH), and an Attending Physician of Family Medicine at Taipei City Hospital. He is currently Director of The American Academy of Anti-Aging Medicine (A4M) of Taiwan, China, and Singapore, Director of Chinese Functional Medicine Association (CFMA), Director of REDOX Integrative Functional Medicine Center and Director of REDOX Biomedicine CO., LTD.